Seres Therapeutics (MCRB) News Today $8.29 -0.26 (-3.04%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$8.18 -0.11 (-1.39%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of "Hold" by AnalystsMay 8 at 2:25 AM | americanbankingnews.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7 at 3:00 PM | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7 at 2:53 PM | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7 at 7:00 AM | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6 at 11:01 PM | msn.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by BrokeragesSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has received a consensus recommendation of "Hold" from the five brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two havMay 5 at 4:10 AM | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What HappenedSeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50-Day Moving Average - What's Next?May 4, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.comStockNews.com lowered Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday.May 3, 2025 | marketbeat.comSeres Therapeutics (MCRB) Projected to Post Quarterly Earnings on WednesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-seres-therapeutics-inc-stock/)May 2, 2025 | marketbeat.comSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short InterestSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 763,100 shares, a decline of 95.2% from the March 31st total of 16,010,000 shares. Based on an average daily volume of 70,300 shares, the short-interest ratio is currently 10.9 days. Approximately 12.0% of the shares of the company are sold short.April 28, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What HappenedSeres Therapeutics (NASDAQ:MCRB) Reaches New 52-Week Low - Here's What HappenedApril 25, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Still a Buy?Seres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Should You Buy?April 24, 2025 | marketbeat.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Hold" from BrokeragesSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has been given an average rating of "Hold" by the five ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommApril 9, 2025 | marketbeat.comFY2025 Earnings Estimate for MCRB Issued By Chardan CapitalSeres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) - Analysts at Chardan Capital increased their FY2025 earnings per share (EPS) estimates for Seres Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will eMarch 28, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)Chardan Capital reiterated a "buy" rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Thursday.March 21, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group cut their price target on Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating for the company in a research note on Friday.March 15, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comSeres Therapeutics (MCRB) Gets a Hold from Piper SandlerMarch 14, 2025 | markets.businessinsider.comSeres Therapeutics reports FY24 EPS (81c), consensus (20c)March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finanznachrichten.deSeres Therapeutics announces anticipated upcoming milestonesMarch 13, 2025 | markets.businessinsider.comSeres Therapeutics sees cash runway into 1Q26March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSeres Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 13, 2025 | seekingalpha.comSeres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.comStockNews.com upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.March 7, 2025 | marketbeat.comSeres Therapeutics (MCRB) Expected to Announce Earnings on ThursdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comSeres Therapeutics receives feedback from FDA on SER-155 development approachMarch 4, 2025 | markets.businessinsider.comSeres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025March 4, 2025 | globenewswire.comSeres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development ApproachMarch 3, 2025 | globenewswire.comSeres Therapeutics (MCRB) to Release Earnings on TuesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comSeres Therapeutics EVP sells $2,704 in stockFebruary 22, 2025 | investing.comSeres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 SharesSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) CEO Eric D. Shaff sold 12,726 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the sale, the chief executive officer now owns 192,039 shares of the company's stock, valued at $155,551.59. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 20, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells $10,308.06 in StockFebruary 20, 2025 | insidertrades.comVontobel Holding Ltd. Has $780,000 Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)Vontobel Holding Ltd. grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 137.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 938,295 shares of the biotechnology company's stockFebruary 19, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Upgraded to "Hold" at StockNews.comStockNews.com upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.February 15, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50 Day Moving Average - Time to Sell?Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.comSeres Therapeutics expands board, appoints new directorFebruary 6, 2025 | msn.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Here's WhySeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - What's Next?January 28, 2025 | marketbeat.comSeres Therapeutics announces receipt of expected $50M installment paymentJanuary 16, 2025 | markets.businessinsider.comSeres Receives $50 Mln Installment Payment Towards Sale Of VOWST Business To Nestle Health ScienceJanuary 16, 2025 | markets.businessinsider.comSeres Therapeutics receives $50 million from Nestlé Health ScienceJanuary 16, 2025 | msn.comSeres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST SaleJanuary 16, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to "Sell"StockNews.com lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.January 11, 2025 | marketbeat.com Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼-0.160.64▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼112▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TKNO News Today SEPN News Today ATYR News Today FULC News Today AURA News Today ATAI News Today CYRX News Today ATXS News Today TERN News Today GLUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MCRB Stock Free MCRB Stock Alerts